Franklin Genomic Advancements ETF Rating $42.10 +0.27 (+0.65%) As of 10:29 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Franklin Genomic Advancements ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.HELX Aggregate RatingModerate Buy 2.78Holdings in HELX have an aggregate rating of Moderate Buy based on 420 analyst ratings issued in the past year covering 24 companies (72.5% of the portfolio).HELX Aggregate Price Target$42.10High Prediction$42.10Average Prediction$42.10Low Prediction$42.10Holdings in HELX have an aggregate price target of $42.10 and a range of $42.10 to $42.10 covering 24 companies (72.5% of the portfolio).HELX Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy3 Buy rating(s)Moderate Buy18 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Franklin Genomic Advancements ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 24 HELX Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings9.20%GHGuardant Health$177.17+0.9%2.2145 of 5 stars2.96$188.13 6.2%26Analyst Forecast8.49%NTRANatera$348.68-0.6%1.9584 of 5 stars2.83$330.83 -5.1%23Positive News5.96%KRYSKrystal Biotech$344.77+2.4%3.1373 of 5 stars2.92$365.40 6.0%13Positive News4.35%LGNDLigand Pharmaceuticals$275.03-0.7%4.1287 of 5 stars3.00$335.75 22.1%9Positive NewsInsider Trade4.31%ADPTAdaptive Biotechnologies$27.45+2.9%1.9283 of 5 stars2.57$24.42 -11.0%73.68%TWSTTwist Bioscience$144.20+4.4%1.8326 of 5 stars2.50$98.45 -31.7%12Gap Up3.34%BBIOBridgeBio Pharma$69.11+1.0%3.7605 of 5 stars2.83$102.61 48.5%23Options Volume3.17%TVTXTravere Therapeutics$63.17+1.1%1.8422 of 5 stars2.75$68.00 7.6%12Positive News2.91%VRTXVertex Pharmaceuticals$514.500.0%3.5479 of 5 stars2.96$570.83 10.9%232.73%CTVACorteva$82.17-1.5%2.7926 of 5 stars2.61$91.67 11.6%23Trending NewsAnalyst Forecast2.64%MEDPMedpace$618.92-0.3%2.5 of 5 stars2.25$595.20 -3.8%12Positive NewsAnalyst Forecast2.36%UTHRUnited Therapeutics$501.34+0.2%4.3211 of 5 stars2.85$646.00 28.9%13Insider Trade2.35%LLYEli Lilly and Company$1,144.08+0.7%4.8073 of 5 stars2.87$1,304.86 14.1%30Trending NewsAnalyst UpgradeAnalyst Revision2.29%REGNRegeneron Pharmaceuticals$776.58+0.3%3.8791 of 5 stars2.58$802.18 3.3%241.91%RGENRepligen$174.35-0.2%2.9859 of 5 stars3.00$168.57 -3.3%18Positive News1.79%TEMTempus AI$69.39+0.8%1.8701 of 5 stars2.43$69.33 -0.1%211.63%NBIXNeurocrine Biosciences$150.33+0.2%4.733 of 5 stars2.88$201.09 33.8%24Positive NewsInsider Trade1.54%CRLCharles River Laboratories International$276.46+1.3%2.1758 of 5 stars2.67$265.69 -3.9%15Positive News1.48%JAZZJazz Pharmaceuticals$242.33+0.6%4.4346 of 5 stars3.00$286.72 18.3%18Insider Trade1.35%CDNACareDx$53.29+1.2%2.5404 of 5 stars2.63$51.20 -3.9%81.28%PRAXPraxis Precision Medicines$310.73-0.7%3.0576 of 5 stars2.95$585.95 88.6%21Positive News1.27%BNTXBioNTech$96.62-0.1%4.121 of 5 stars2.68$126.00 30.4%19Analyst ForecastInsider Trade1.21%GRALGRAIL$76.74+1.1%0.6318 of 5 stars2.36$71.11 -7.3%11Positive NewsAnalyst UpgradeOptions Volume1.21%PTCTPTC Therapeutics$67.29+2.5%3.6442 of 5 stars2.67$98.50 46.4%15Analyst Forecast This page (BATS:HELX) was last updated on 9/16/2026 by MarketBeat.com Staff. From Our Partners“This is the Perfect Tech Stock”Jeff Brown, the tech investor who identified Nvidia in 2016 before its 37,000% run, has flagged a new AI compa...Brownstone Research | SponsoredA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredGold just passed our debt as the world's #1 assetChina's US Treasury holdings have fallen from a peak of $1.32 trillion to roughly $659 billion, an 18-year low...Behind the Markets | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredNNVC on Alert: FDA Validation and Outperform Rating!NanoViricides (NYSE: NNVC) just landed FDA Rare Pediatric Disease Designation for NV-387 in Measles, adding to...Equiscreen | SponsoredWhat Is A Roth Conversion, And How Do I Set One Up?A Roth conversion moves money from a traditional IRA or employer plan into a Roth IRA, triggering income tax t...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Franklin Genomic Advancements ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Franklin Genomic Advancements ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HELX Stock Alerts